At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 126 target
Drug / intervention
Envafolimabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open, Single-arm, Multi-center Phase II Clinical Study of ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating Envafolimab for Solid Tumor. Currently recruiting, targeting 126 participants across 1 site.
Detailed Summary
An open, single-arm, multi-center Phase II clinical study of ENVAFOLIMAB single-agent treatment in patients with advanced solid tumors,to compare the overall response rate of TMB-high and TMB-Low,to determine the cut off value between TMB-high and TMB-Low of diagnosis device.Then,observe the efficacy of ENVAFOLIMAB uesd comfirmed TMB-H Value
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
2022202320242025202620272028
First PostedMay 2021
Enrollment StartAug 2021
TodayJul 2026
Primary CompletionAug 2027
Study CompletionApr 2028
First PostedMay 18, 2021
Enrollment StartAug 6, 2021
Primary CompletionAug 30, 2027
Study CompletionApr 30, 2028
TodayJul 1, 2026
Enrollment to primary: 6.1 yearsPosted 5.1 years agoPrimary completion in 1.2 years
Interventions
Envafolimabdrug
Subcutaneous injection